Cutting-Edge Research in Acute Myocardial Infarction

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 1155

Special Issue Editors

University Hospital Sf. Spiridon, Iasi, Romania
Interests: cardiology; acute myocardial infarction
1. Institute of Cardiovascular Diseases “Prof. Dr. George I.M. Georgescu”, 700503 Iasi, Romania
2. Faculty of Medicine, University of Medicine and Pharmacy “Grigore T Popa”, 700115 Iasi, Romania
3. Medical Sciences Academy, 030167 Bucharest, Romania
Interests: cardionephrology; AI; chronical respiratory diseases; gut microbiota; interventional cardiology; research methodology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Myocardial infarction is one of the leading causes of cardiovascular disease-related morbidity and mortality in the developed world and has maintained its status as a major international health problem despite exceptional recent advances in its diagnosis and treatment.

This Special Issue aims to provide a comprehensive picture of the latest research in the field of myocardial infarction. We encourage the coverage of a wide range of topics and perspectives, including current progress in basic science, the underlying mechanisms of myocardial infarction, and areas such as immunomodulation, endothelial function, and genetics.

Furthermore, this issue welcomes cutting-edge review articles and original research papers on the most recent developments and future perspectives in diagnostic (e.g., artificial intelligence, deep learning, and neural networks) and therapeutic strategies (e.g., particular invasive reperfusion strategies, mechanical circulatory support, and cardiogenic shock management) for acute myocardial infarction.

Contributions may be related to any aspect of AMI (e.g., secondary prevention strategies, telemedicine, long-term prognosis, or nationwide surveys) and should expand on the existing knowledge surrounding such topics.

Dr. Dan Tesloianu
Dr. Alexandru Burlacu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • acute myocardial infarction
  • imaging
  • invasive reperfusion strategies
  • STEMI
  • NSTE-ACS
  • cardiogenic shock
  • mechanical circulatory support
  • artificial intelligence
  • endothelial function
  • secondary prevention strategies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 945 KiB  
Article
Changes in Antithrombotic Therapy Prescription in Patients with a Combination of Atrial Fibrillation and Myocardial Infarction in a Specialised Inpatient Department from 2016–2019 and Associations with Prognosis
Medicina 2023, 59(9), 1556; https://doi.org/10.3390/medicina59091556 - 27 Aug 2023
Viewed by 935
Abstract
Background and Objectives: The problem of treating patients with atrial fibrillation and myocardial infarction is relevant. The issue of optimal antithrombotic therapy in these patients has not been definitively resolved. This work analyzes the influence of clinical factors and treatment on the [...] Read more.
Background and Objectives: The problem of treating patients with atrial fibrillation and myocardial infarction is relevant. The issue of optimal antithrombotic therapy in these patients has not been definitively resolved. This work analyzes the influence of clinical factors and treatment on the long-term prognosis of patients. Materials and Methods: The research included 360 patients with atrial fibrillation and myocardial infarction during 2016–2019. Results: The factors associated with fatal outcomes were age (hazard ratio (HR): 1.05; 95% confidence interval (CI): 1.03–1.07; p < 0.001); stroke (HR: 1.95; 95% CI: 1.27–3.00; p = 0.0002); glomerular filtration rate (HR: 0.988; 95% CI: 0.978–0.998; p = 0.03); left ventricular ejection fraction (HR: 0.975; 95% CI: 0.957–0.999; p = 0.007); and aspirin (HR: 0.48; 95% CI: 0.31–0.73; p < 0.001). The factors associated with the combined endpoint were chronic kidney disease (HR: 1.46; 95% CI: 1.01–2.10; p = 0.04); HAS-BLED (HR: 1.23; 95% CI: 1.06–1.43; p = 0.007); percutaneous coronary intervention (HR: 0.70; 95% CI: 0.51–0.96; p = 0.03); and aspirin (HR: 0.65; 95% CI: 0.44–0.97; p = 0.03). Conclusions: Double and triple antithrombotic therapy were not associated with outcomes. Aspirin improved the prognosis for survival and the combined endpoint. Full article
(This article belongs to the Special Issue Cutting-Edge Research in Acute Myocardial Infarction)
Show Figures

Figure 1

Back to TopTop